| pubmed-article:20347138 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20347138 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:20347138 | lifeskim:mentions | umls-concept:C0345904 | lld:lifeskim |
| pubmed-article:20347138 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:20347138 | lifeskim:mentions | umls-concept:C0246249 | lld:lifeskim |
| pubmed-article:20347138 | lifeskim:mentions | umls-concept:C0024485 | lld:lifeskim |
| pubmed-article:20347138 | lifeskim:mentions | umls-concept:C1450054 | lld:lifeskim |
| pubmed-article:20347138 | lifeskim:mentions | umls-concept:C2346689 | lld:lifeskim |
| pubmed-article:20347138 | lifeskim:mentions | umls-concept:C2827155 | lld:lifeskim |
| pubmed-article:20347138 | pubmed:issue | 18 | lld:pubmed |
| pubmed-article:20347138 | pubmed:dateCreated | 2010-4-19 | lld:pubmed |
| pubmed-article:20347138 | pubmed:abstractText | To develop a drug delivery system with enhanced efficacy and minimized adverse effects, we synthesized a novel polymeric nanoparticles, (YCC-DOX) composed of poly (ethylene oxide)-trimellitic anhydride chloride-folate (PEO-TMA-FA), doxorubicin (DOX) and superparamagnetic iron oxide (Fe(3)O(4)) and folate. The efficacy of the nanoparticles was evaluated in rats and rabbits with liver cancer, in comparison with free-DOX (FD) and a commercial liposome drug, DOXIL. YCC-DOX showed the anticancer efficacy and specifically targeted folate receptor (FR)-expressing tumors, thereby increasing the bioavailability and efficacy of DOX. The relative tumor volume of the YCC-DOX group was decreased two- and four-fold compared with the FD and DOXIL groups in the rat and rabbit models, respectively. Furthermore, YCC-DOX showed higher MRI sensitivity comparable to a conventional MRI contrast agent (Resovist), even in its lower iron content. In the immunohistochemical analysis, YCC-DOX group showed the lower expression of CD34 and Ki-67, markers of angiogenesis and cell proliferation, respectively, while apoptotic cells were significantly rich in the YCC-DOX group in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. These results indicate that YCC-DOX is a promising candidate for treating liver cancer and monitoring the progress of the cancer using MRI. | lld:pubmed |
| pubmed-article:20347138 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20347138 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347138 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20347138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347138 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20347138 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:20347138 | pubmed:issn | 1878-5905 | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:LeeJeongmiJ | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:JeongSeokS | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:ShimChang-Koo... | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:KimWon-HongWH | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:ParkIn-SuhIS | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:MaengJin... | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:HongSoon-SunS... | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:LeeDon-HaengD... | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:JungKyung... | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:KimJi-HeeJH | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:KimJungahnJ | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:LeeYoon-MiYM | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:KimWooyoungW | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:BaeYou-HanYH | lld:pubmed |
| pubmed-article:20347138 | pubmed:author | pubmed-author:JeonYong-SunY... | lld:pubmed |
| pubmed-article:20347138 | pubmed:copyrightInfo | (c) 2010. Published by Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20347138 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20347138 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:20347138 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20347138 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20347138 | pubmed:pagination | 4995-5006 | lld:pubmed |
| pubmed-article:20347138 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:meshHeading | pubmed-meshheading:20347138... | lld:pubmed |
| pubmed-article:20347138 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20347138 | pubmed:articleTitle | Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. | lld:pubmed |
| pubmed-article:20347138 | pubmed:affiliation | Utah-Inha DDS Institute, Annex B-403, Meet-You-All tower, Songdo Technopark, 7-50, Songdo-dong, Yeonsu-gu, Incheon 406-840, South Korea. | lld:pubmed |
| pubmed-article:20347138 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20347138 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20347138 | lld:pubmed |
